X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (433) 433
humans (419) 419
treatment-naive patients (269) 269
treatment-naive (238) 238
female (197) 197
male (195) 195
adult (166) 166
infectious diseases (159) 159
pharmacology & pharmacy (156) 156
middle aged (148) 148
hiv infections - drug therapy (141) 141
hepatitis c (138) 138
antiviral agents - therapeutic use (131) 131
hiv (131) 131
ribavirin (131) 131
virology (128) 128
hepatitis c, chronic - drug therapy (127) 127
hepatitis c virus (118) 118
antiviral agents (117) 117
treatment outcome (117) 117
drug therapy (115) 115
genotype (114) 114
human immunodeficiency virus--hiv (112) 112
drug therapy, combination (103) 103
hepatitis (102) 102
hepacivirus - genetics (100) 100
mutation (96) 96
antiretroviral therapy (95) 95
research (95) 95
drug resistance (94) 94
protease inhibitors (90) 90
virus diseases (88) 88
interferon (87) 87
therapy (87) 87
hiv infections - virology (85) 85
drug resistance, viral (83) 83
treatment-experienced patients (83) 83
health aspects (82) 82
viruses (82) 82
care and treatment (80) 80
antiretroviral drugs (79) 79
infection (79) 79
infections (79) 79
microbiology (79) 79
patients (78) 78
gastroenterology & hepatology (76) 76
medicine (75) 75
research article (74) 74
genotype 1 infection (73) 73
hiv-1 - drug effects (70) 70
immunology (70) 70
hepacivirus - drug effects (68) 68
sofosbuvir (68) 68
clinical trials (67) 67
hiv-1 - genetics (67) 67
aged (65) 65
multidisciplinary sciences (64) 64
anti-hiv agents - therapeutic use (63) 63
hcv (63) 63
viral load (62) 62
double-blind (60) 60
sustained virological response (60) 60
science (59) 59
human immunodeficiency virus (58) 58
analysis (56) 56
combination therapy (56) 56
review (55) 55
dosage and administration (54) 54
ribavirin - therapeutic use (54) 54
acquired immune deficiency syndrome--aids (53) 53
hepatitis c, chronic - virology (53) 53
hiv infection (53) 53
young adult (53) 53
pegylated interferon (52) 52
open-label (50) 50
virus-infection (50) 50
antiviral agents - administration & dosage (49) 49
aids (48) 48
genotype & phenotype (48) 48
safety (48) 48
studies (48) 48
efficacy (47) 47
antiviral agents - adverse effects (46) 46
article (45) 45
hepatitis c - drug therapy (45) 45
genetic aspects (44) 44
cirrhosis (43) 43
drug resistance, viral - genetics (42) 42
hiv-1 (42) 42
mutations (42) 42
plus ribavirin (42) 42
adolescent (41) 41
efavirenz (41) 41
resistance (41) 41
risk factors (41) 41
antiretroviral agents (40) 40
prevalence (40) 40
usage (40) 40
hepatology (39) 39
genotypes (38) 38
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2013, Volume 207, Issue 5, pp. 740 - 748
Journal Article
Clinical Microbiology and Infection, ISSN 1198-743X, 2018, Volume 25, Issue 3, pp. 365 - 371
Objective: To investigate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or simeprevir (SMV) in a randomized, open-label, noninferiority... 
Daclatasvir | Simeprevir | Randomized clinical trial | Hepatitis C | Sofosbuvir | INFECTIOUS DISEASES | MICROBIOLOGY | RIBAVIRIN | PHASE-3 | REGIMENS | TREATMENT-NAIVE | REAL-WORLD | PLUS SOFOSBUVIR | CIRRHOSIS | HCV
Journal Article
HIV Medicine, ISSN 1464-2662, 05/2015, Volume 16, Issue 5, pp. 288 - 296
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 5, p. e19461
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 03/2019, Volume 74, Issue 3, pp. 746 - 753
Abstract Objectives In subjects with transmitted thymidine analogue mutations (TAMs), boosted PIs (PI/b) are often chosen to overcome possible resistance to... 
INDIVIDUALS | INFECTIOUS DISEASES | TRANSMISSION | HIV | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | ANTIRETROVIRAL TREATMENT | REGIMENS | TREATMENT-NAIVE PATIENTS | Original Research
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2014, Volume 54, Issue 6, pp. 640 - 648
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2/2017, Volume 56, Issue 2, pp. 153 - 163
The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen)... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | SERUM CREATININE | TRIAL | VIVO ANTIVIRAL ACTIVITY | IN-VITRO | ABT-450/R-OMBITASVIR | INTERFERON | TREATMENT-NAIVE | PHARMACOLOGY & PHARMACY | HCV | RESISTANCE PROFILE | RIBAVIRIN | Antiviral Agents - pharmacokinetics | Anilides - adverse effects | Humans | Middle Aged | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Hepacivirus - metabolism | Ritonavir - adverse effects | Uracil - administration & dosage | Kidney Diseases - epidemiology | Female | Kidney Diseases - blood | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Hepacivirus - drug effects | Ritonavir - administration & dosage | Kidney Diseases - drug therapy | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Uracil - adverse effects | Anilides - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Care and treatment | Usage | Diagnosis | Hepatitis C virus | Ritonavir | Proteins | Survival analysis | Hepatitis | Comorbidity | Liver | Infections | Interferon | Family medical history | Kidney diseases | Drug dosages | Pharmaceuticals
Journal Article
HIV Medicine, ISSN 1464-2662, 08/2017, Volume 18, Issue 7, pp. 482 - 489
Journal Article